News articles about Cotiviti (NYSE:COTV) have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cotiviti earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned media headlines about the business services provider an impact score of 45.8743430725515 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Shares of Cotiviti stock opened at $34.10 on Tuesday. The firm has a market capitalization of $3,142.34, a PE ratio of 24.01, a P/E/G ratio of 1.56 and a beta of 0.82. The company has a quick ratio of 1.73, a current ratio of 1.73 and a debt-to-equity ratio of 0.68. Cotiviti has a 12-month low of $30.84 and a 12-month high of $45.97.
Cotiviti (NYSE:COTV) last issued its quarterly earnings results on Wednesday, February 21st. The business services provider reported $0.47 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.43 by $0.04. The firm had revenue of $176.70 million during the quarter, compared to analysts’ expectations of $179.43 million. Cotiviti had a net margin of 20.36% and a return on equity of 13.29%. Cotiviti’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.39 EPS. research analysts expect that Cotiviti will post 1.68 earnings per share for the current year.
Several research analysts have recently issued reports on COTV shares. Zacks Investment Research cut shares of Cotiviti from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 2nd. Citigroup started coverage on shares of Cotiviti in a report on Thursday, January 4th. They issued a “buy” rating for the company. Finally, First Analysis cut shares of Cotiviti from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $48.00 to $40.00 in a report on Friday, February 23rd. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. Cotiviti presently has a consensus rating of “Hold” and a consensus target price of $41.14.
In related news, COO David Beaulieu sold 15,000 shares of the stock in a transaction on Friday, January 19th. The shares were sold at an average price of $35.00, for a total transaction of $525,000.00. Following the completion of the sale, the chief operating officer now owns 49,573 shares in the company, valued at approximately $1,735,055. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO J Douglas Williams sold 30,000 shares of the stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $33.60, for a total transaction of $1,008,000.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 185,000 shares of company stock valued at $6,405,250. 15.80% of the stock is owned by company insiders.
TRADEMARK VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Cotiviti (COTV) Stock Price” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/17/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-cotiviti-cotv-stock-price.html.
Cotiviti Holdings, Inc, through its subsidiaries, provides analytics-driven payment accuracy and spend management solutions primarily for the healthcare sector in the United States, Canada, the United Kingdom, and India. It operates through two segments, Healthcare, and Global Retail and Other. The company offers prospective claims accuracy solutions that enable healthcare clients identify and address claim discrepancies immediately following claim adjudication and before a claim is paid to a healthcare provider; and retrospective claims accuracy solutions that enable health insurers identify and resolve payment inaccuracies after a claim has been paid to a healthcare provider.
Receive News & Ratings for Cotiviti Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cotiviti and related companies with MarketBeat.com's FREE daily email newsletter.